


EN1/FANDANGO

Trial setting: A randomised double-blind placebo-controlled phase II trial of first line combination chemo-therapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer

Study Design:



Sponsor(s): NSGO

Planned No. of patients: 148

Current accrual: 42


Other important information: Status - recruiting

Stratification:

- Stage of disease (stage 3C 2 vs. stage 4 vs. recurrent disease)
- Prior adjuvant chemotherapy (yes/no)
- Disease status (Measurable vs. non-measurable disease according to RECIST 1.1)



Ongoing Trials – status update



EN1/FANDANGO



A randomised double-blind placebo-controlled phase II trial of first line combination chemo-therapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer.

Country	NC	Submission status	Number of Sites	Number of Sites Activated	Screened patients	Randomized Patients
Denmark	Dr. Mansoor Raza Mirza	CA: APPROVED 21.06.16 EC: APPROVED 02.08.16	4	4	10	9
Finland	Dr. Johanna Mäenpää	CA: APPROVED 10.06.16 EC: APPROVED 17.08.16	2	2	1	1
Norway	Dr. Kristina Lindemann	CA: APPROVED 25.08.16 EC: APPROVED 11.11.16	1	1	6	6
Sweden	Dr. Gabriel Lindahl	CA: APPROVED 21.06.16 EC: APPROVED 18.05.16	4	4	4	4
Belgium BGOG	Dr. Sevilay Altintas	CA: APPROVED 27.10.16 EC: APPROVED 02.03.17	6	6	5	4
France GINECO	Dr. Dominique Berton-Rigaud	CA: APPROVED 30.11.16 EC: APPROVED 22.11.16	12	12	17	12
Germany NOGGO	Dr. Jalid Sehouli	CA: APPROVED 09.09.16 EC: APPROVED 16.09.16	12	11	12	10
TOTAL			41	40	55	46